Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study…
Bausch Health to Appeal XIFAXAN Patent Decision to U.S. Court of Appeals for the Federal Circuit, Says Expects Decision To Issue Within 12-18 Months
Bausch Health Companies Inc. (TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press release, the U.S. District Court
This Analyst Says Zentalis’ Increased Focus On WEE1 Program Is ‘Prudent’, Slashes Price Target By 37%
Zentalis Pharmaceuticals Inc (NASDAQ:ZNTL) decided to discontinue the development of oral SERD asset ZN-c5 and EGFR inhibitor ZN-e4 following the completion…
Rani Therapeutics Announces Topline Results from Phase 1 Study of RT-102 in Osteoporosis
Rani Therapeutics Holdings, Inc. ("Rani Therapeutics" or "Rani") (NASDAQ:RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced positive
ReShape Lifesciences’ GIBI HD Calibration Tubes Scores FDA Approval For Tummy Tuck Procedures
ReShape Lifesciences Inc (NASDAQ:RSLS) has received FDA 510(k) clearance for the disposable Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for…
ReShape Lifesciences Shares Soar As FDA Announced Clearance To GIBI HD Calibration Tubes In Weight Loss Procedures
The U.S. Food and Drug Administration (FDA) has announced 510(k) clearance to ReShape Lifesciences’ (NASDAQ: RSLS) Gastro Intestinal Balloon Indicator (GIBI HD) calibration tube for use in gastric and bariatric surgical procedures.
ReShape Lifesciences Receives FDA 510(k) Clearance For GIBI HD Calibration Tubes For Use In Gastric and Bariatric Procedures
New Calibration Tubes, in Three Sizes, Will Simplify Gastric and Bariatric Procedures Including Laparoscopic Sleeve Gastrectomy, Gastric Bypass and Gastric Banding
Company to Introduce Product at IFSO 2022 World
Lexaria Gets FDA’s Positive Feedback On Pre-Clinical Trial Of Hypertension Candidate
Lexaria Bioscience Corp. (NASDAQ: LEXX) announced that it has received a positive full written response from the Food and Drug Administration (FDA) from its pre-Investigational New Drug meeting regarding DehydraTECH-CBD for the treatment of hypertension.
Biotech Daily: Cancer Causing Impurities In Merck’s Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon’s Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours:
GSK Confirms Rotavirus Vaccine Shortage, Hits Four African Countries: Report
After disruptions at GSK plc (NYSE:GSK), supplies of rotavirus infection vaccine in children have either run out in Kenya, Tanzania,…